Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 1/20 | 0.33 |
| ▸ | FBP1 | P09467 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | ERO1A | Q96HE7 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | RORC | P51449 | 1/20 | 0.30 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1738979 | 0.90 | KMT2A (0.34) | FBP1KMT2AMEN1 | |
| SCHEMBL1739946 | 0.87 | FBP1 (0.32) | FBP1KMT2AMEN1 | |
| SCHEMBL692914 | 0.81 | CMA1 (0.32) | CMA1ERO1A | |
| SCHEMBL699507 | 0.80 | FBP1 (0.38) | FBP1KMT2AMEN1 | |
| SCHEMBL13092333 | 0.78 | AMY1A (0.37) | CMA1ERO1A | |
| SCHEMBL1738906 | 0.78 | MDM2 (0.42) | KMT2A | |
| SCHEMBL7842206 | 0.78 | KMT2A (0.33) | KMT2AMEN1P2RX3 | |
| SCHEMBL3662809 | 0.78 | KMT2A (0.33) | KMT2AMEN1P2RX3 | |
| SCHEMBL1739882 | 0.77 | FBP1 (0.40) | FBP1KMT2AMEN1 | |
| SCHEMBL1740272 | 0.77 | FBP1 (0.40) | FBP1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2389381-A1 | SPIROINDOLINONE DERIVATIVE PRODRUGS | F. Hoffmann-La Roche AG (CH) | 2011-11-30 | — | — | EP | disclosed |
| US-8038247-B2 | Recording apparatus and recording method | CANON KABUSHIKI KAISHA (JP) | 2011-10-18 | — | — | US | disclosed |
| US-7776875-B2 | such as 2'S,3S,4'R)-6-chloro-4'-{5-chloro-2-[1-methyl-1-(1-methyl-piperidin-4-ylcarbamoyl)-ethoxy]-phenyl}-2'-(5-fluoro-2-methyl-phenyl)spiro[3H-indole-3,3'-piperidine]-2,6'(1H)-dione, used as antiproliferative agents, especially, as anticarcinogenic agents | HOFFMAN-LA ROCHE INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-7776875-B2 | such as 2'S,3S,4'R)-6-chloro-4'-{5-chloro-2-[1-methyl-1-(1-methyl-piperidin-4-ylcarbamoyl)-ethoxy]-phenyl}-2'-(5-fluoro-2-methyl-phenyl)spiro[3H-indole-3,3'-piperidine]-2,6'(1H)-dione, used as antiproliferative agents, especially, as anticarcinogenic agents | HOFFMAN-LA ROCHE INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-20100190814-A1 | SPIROINDOLINONE DERIVATIVE PRODRUGS | CHEN LI | 2010-07-29 | — | — | US | disclosed |
| US-20100190814-A1 | SPIROINDOLINONE DERIVATIVE PRODRUGS | CHEN LI | 2010-07-29 | — | — | US | disclosed |
| WO-2010084097-A1 | SPIROINDOLINONE DERIVATIVE PRODRUGS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-07-29 | — | — | WO | disclosed |
| US-20090163512-A1 | such as 2'S,3S,4'R)-6-chloro-4'-{5-chloro-2-[1-methyl-1-(1-methyl-piperidin-4-ylcarbamoyl)-ethoxy]-phenyl}-2'-(5-fluoro-2-methyl-phenyl)spiro[3H-indole-3,3'-piperidine]-2,6'(1H)-dione, used as antiproliferative agents, especially, as anticarcinogenic agents | CHEN LI | 2009-06-25 | — | — | US | disclosed |
| US-20090163512-A1 | such as 2'S,3S,4'R)-6-chloro-4'-{5-chloro-2-[1-methyl-1-(1-methyl-piperidin-4-ylcarbamoyl)-ethoxy]-phenyl}-2'-(5-fluoro-2-methyl-phenyl)spiro[3H-indole-3,3'-piperidine]-2,6'(1H)-dione, used as antiproliferative agents, especially, as anticarcinogenic agents | CHEN LI | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190814-A1 | SPIROINDOLINONE DERIVATIVE PRODRUGS | CCNE1, CCNE2, CCND1 | CMA1 4578/4885FBP1 2140/4885KMT2A 1443/4885 |
| US-20090163512-A1 | such as 2'S,3S,4'R)-6-chloro-4'-{5-chloro-2-[1-methyl-1-(1-methyl-piperidin-4-ylcarbamoyl)-ethoxy]-phenyl}-2'-(5-fluoro-2-methyl-phenyl)spiro[3H-indole-3,3'-piperidine]-2,6'(1H)-dione, used as antiproliferative agents, especially, as anticarcinogenic agents | TOP2B, TOP2A, CCNY | CMA1 3345/4885FBP1 2308/4885KMT2A 416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.